Reactions Weekly

, Volume 1695, Issue 1, pp 221–221 | Cite as

Inotuzumab ozogamicin

Acute cholecystitis: case report
Case report


  1. Khouri IF, et al. Safety of addition of inotuzumab ozogamicin (CMC 544) to bendamustine, fludarabine, and rituximab (BFR) allogeneic conditioning for lymphoid malignancies. Blood 130 (Suppl. 1): 3240, 2017. Available from: URL: [abstract] -USA

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations